Denator AB, a Sweden-based biotechnology and manufacturing company established in 2004, specializes in developing and marketing products designed to stabilize biological tissues and fluids from the moment of sampling. This innovative approach significantly enhances the quality of data obtained from downstream analytical techniques.
In the realm of protein studies, this advancement enables enhanced data quality, thereby increasing the reliability of data interpretation and potentially revealing novel proteins and peptides that would otherwise be lost or undetectable when using conventional preparation techniques. Denator's proprietary heat stabilization technology serves as the foundation for developing solutions that allow scientists to immediately stop sample degradation and maintain the stability of sample components throughout the analytical workflow.
Notably, Denator received a grant investment of €50.00K from EASME - EU Executive Agency for SMEs on 01 July 2015. This funding is a testament to Denator's potential impact in the biotechnology industry and its commitment to advancing the quality and reliability of analytical data in scientific research.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €50.00K | 1 | EASME - EU Executive Agency for SMEs | 01 Jul 2015 |
| Series F | kr25.50M | 1 |
|
04 Apr 2012 |
| Venture Round | $1.70M | 4 | T-bolaget, Wikow Ventures +2 | 10 Jan 2011 |
| Series B | $2.16M | 2 |
|
01 Feb 2007 |
| Series A | $664.00K | 1 | T-bolaget | 20 Apr 2006 |
No recent news or press coverage available for Denator AB.
We care about your data, and we'd love to use cookies make your experience better.
